January 6, 2011 by staff
Medical Officer, Boston Scientific Corporation (NYSE: BSX) today issued the following statement by Kenneth Stein, MD, and chief medical officer, Cardiac Rhythm Management, on an article that was published online today in the Journal of the American Medical Association. The article reports a study that about 20 percent of patients who received an implantable cardiac defibrillator (ICD) does not meet guidelines based on evidence of receiving one.
“Guidelines represent a consensus of the scientific community that a given procedure or treatment is beneficial, useful and effective. Boston Scientific is proud to have sponsored numerous clinical trials that have provided the scientific basis of the guidelines referenced in the JAMA article.
“However, it is important to place these results in their appropriate clinical context Sudden Cardiac Arrest (SCA) is the most common cause of death in the U.S. About 460,000 Americans die each year from SCA. This is more than lung cancer, breast cancer and HIV-related illnesses combined. Currently, more than one million patients are eligible for an ICD, but only a small percentage of patients actually receive the lifesaving device. In fact, Previous studies show that ICDs are used in only 20-40 percent of patients reported in the U.S.
“Dr. Sana Al-Khatib has made important contributions to address the under-utilization of therapy device for the prevention of SCA. She played a key role in the organization of sudden cardiac arrest Thought Leadership Alliance a reflection group on the issue, which met in December 2009 this meeting, resulted in a recent publication on the question. “Fight against disparities in the care of sudden cardiac arrest and the underuse of effective therapies.” His main conclusion was: “Despite overwhelming evidence of clinical trials, expert opinion, national guidelines, and a wide range of educational conferences, based on evidence, drugs that prolong life and therapy device continue to be underutilized, with significant disparities in the care of SCA and ICD use among vulnerable populations, including blacks, women and the elderly. ”
“It is interesting to note that three of the four cases cited in the JAMA article were outside the guidelines based solely on the calendar, and many of these patients would have qualified within a few weeks or months.
“ICD and cardiac resynchronization therapy defibrillator (CRT-D) therapy proved to be profitable in the MADIT II, SCD-HeFT companion and clinical patient populations Trial. Furthermore, data on long-term study MADIT II showed that the benefits of saving ICD therapy were sustained over eight years (34 per cent reduction in relative risk of death). In this trial, we saved the lives of all eight patients who received an ICD.
“While ICDs are sometimes used outside the guidelines, the most fundamental problem is that overall, this salvage therapy is underused, rather than over-used.”
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Please feel free to send if you have any questions regarding this post , you can contact on
Disclaimer: The views expressed on this site are that of the authors and not necessarily that of U.S.S.POST.